Katta klinik sinov natijalari shuni ko'rsatadiki, blinatumomab (Blincyto) bilan kasallangan odamlarni davolashga qo'shiladi. o'tkir limfoblastik leykemiya (ALL) remissiya davrida bo'lganlar, hatto ularning kasalligi belgilari bo'lmasa ham, ularga uzoq umr ko'rishga yordam beradi.
Tadqiqotda, blinatumomabni kimyoterapiya bilan birga berish, remissiyaga o'tgan saraton bilan og'rigan odamlarni faqat kimyoterapiya olganlarga qaraganda ancha uzoqroq umr ko'rdi, bu hozirgi standart davolash. Sinovdagi bemorlar nafaqat remissiyada edi, balki ularning saraton belgilari ham yo'q edi. Bunga egalik deyiladi minimal qoldiq kasallik (MRD)-salbiy ALL.
Sinov natijalari 2022 yil dekabr oyida Yangi Orleanda bo'lib o'tgan Amerika Gematologiya Jamiyatining (ASH) yillik yig'ilishida ko'rsatildi.
In 2018, the Food and Drug Administration (FDA) cleared blinatumomab to treat people with MRD-positive ALL who were in remission but still showed signs of cancer during follow-up tests. Even though recurrences after remission are always possible, people with MRD-positive ALL have a higher chance of their cancer coming back after their first treatment than those who do not have MRD.
ASH yig'ilishida natijalar bo'lmagan odamlar uchun ko'rsatildi MRD birinchi dori-darmonlardan keyin.
Remissiyadan keyingi terapiya boshlanganidan keyin 3.5 yil o'tgach, blinatumomab va kimyoterapiya bilan davolangan bemorlarning 83 foizi hali ham tirik edi, faqat kimyoterapiya bilan davolangan bemorlarning atigi 65 foizi tirik edi.
Blinatumomab MRD-salbiy ALL uchun ham samarali
B-cell ALL is the most common type of ALL in both adults and children. It is a type of qon saratoni that spreads quickly and is very dangerous. Chemotherapy is the standard treatment, and it often leads to remission. However, a lot of people get sick again, even if tests done after treatment show no signs of disease.
Immunoterapiya dori-darmonlari saraton kasalligi remissiyaga o'tgandan keyin uni davolash va uning qaytib kelish xavfini kamaytirish usuli sifatida va'da berdi.
Bir turi immunoterapiya called a bispecific T-cell engager (BiTE) is what blinatumomab is. It sticks to both T cells and cancer cells at the same time. This makes it easy for T cells to find and kill the cancer cell by bringing them closer together. The drug, which is given through an IV, has been shown to be more effective than chemotherapy at treating B-ALL that has come back in children and young adults who have already been treated for it.
NCI yordami bilan ECOG-ACRIN saraton tadqiqot guruhi tomonidan olib borilayotgan ushbu sinov 2013 yilda blinatumomab B-hujayrali ALL tashxisi qo'yilgan odamlarga yordam berishi mumkinligini aniqlash uchun boshlangan.
Sinovda umuman 488 kishi qatnashgan bo'lsa ham, ASHda ko'rsatilgan natijalar odatdagidek boshlang'ich kimyoterapiya rejimlaridan keyin remissiyada bo'lgan va MRD-salbiy bo'lgan 224 kishiga tegishli edi. Bemorlarga blinatumomabdan tashqari ko'proq kimyoterapiya yoki shunchaki kimyoterapiya berildi. Keyin barcha sub'ektlar 2.5 yil davomida har olti oyda kimyoterapiya oldilar. Ba'zi odamlar, agar shifokor buni eng yaxshi deb bilsa, suyak iligi transplantatsiyasini ham oldi.
Kimyoterapiyaga blinatumomabni qo'shish nafaqat umumiy omon qolishni yaxshiladi, balki faqat kimyoterapiya olgan bemorlarga nisbatan saraton kasalligi qaytmasdan uzoq umr ko'rdi.
Doktor Litsovning aytishicha, blinatumomabni qabul qilganlarning hech biri kutilmagan nojo'ya ta'sirlarga ega bo'lmagan. Blinatumomabning eng keng tarqalgan yon ta'siridan ba'zilari isitma, infuzionga javob, bosh og'rig'i, infektsiyalar, titroq va titroqdir.
